⌘K
t
AstraZeneca PLC filed a Block Listing Six Monthly Return on 1 December 2025. For the period from 1 June 2025 to 30 November 2025, the company reported 67,907 securities were issued/allotted under its share option and employee share plans, resulting in a balance of 3,620,476 unallotted securities at the end of the period, down from 3,688,383.
| Date | 1 Dec 2025 |
| Time | 15:05:00 |
| Category | Capital structure |
| ID | 6860J |
1 December 2025
BLOCK LISTING SIX MONTHLY RETURN
Information provided on this form must be typed or printed electronically and provided to a PIP.
(Note: Italicised terms have the same meaning as given in the Listing Rules.)
Date: 1 December 2025
|
Name of applicant: |
ASTRAZENECA PLC |
|||
|
Name of scheme: |
ASTRAZENECA SHARE OPTION PLAN; ASTRAZENECA SAVINGS-RELATED SHARE OPTION PLAN; ASTRAZENECA ALL-EMPLOYEE SHARE PLAN; ASTRAZENECA PLC 2012 SAVINGS-RELATED SHARE OPTION SCHEME |
|||
|
Period of return: |
From: |
1 JUNE 2025 |
To: |
30 NOVEMBER 2025 |
|
Balance of unallotted securities under scheme(s) from previous return: |
3,688,383 |
|||
|
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): |
0 |
|||
|
Less: Number of securities issued/allotted under scheme(s) during period (see UKLR 20.6.7G): |
67,907 |
|||
|
Equals: Balance under scheme(s) not yet issued/allotted at end of period: |
3,620,476 |
|||
|
Name of contact: |
Hannah Tattersall |
|
Telephone number of contact: |
+44 (0)20 3749 5000 |
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca
Contacts
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.
Matthew Bowden
Company Secretary
AstraZeneca PLC